Elizabeth Benz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth Benz has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Hugo Stricker
Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
3 shared publications - Guy Gaston Brusselle
Ghent University Hospital, Ghent, Belgium
3 shared publications - Lies Lahousse
Department of Bioanalysis, Faculty of Pharmaceutical Sciences Ghent University Ghent Belgium
3 shared publications - Fernando Rivadeneira
Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
2 shared publications - Johnmary T. Arinze
Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands
2 shared publications - Katerina Trajanoska
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 15 October 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (5) , e70099
Sarcopenic Obesity Phenotype Index (SOP i ): A Population‐Based Study
Background: Sarcopenic obesity (SO) is a clinical condition defined by the coexistence of high body fat mass and low muscle function and mass, which increases the risk of adverse health outcomes, including disability and mortality. Early detection and frequent monitoring of SO are essential for preventive interventions and management strategies. The current binary approach for SO diagnosis is limited in capturing the spectrum of SO or its progression over time. The main objective of this study was to develop a continuous SOP i that integrates diagnostic criteria such as muscle function and body composition. We aimed to evaluate the association between SOP i and all‐cause mortality, to identify baseline‐related factors with SOP i and to assess changes in the SOP i over time. Methods: Participants from the Rotterdam Study with baseline and follow‐up measures of handgrip strength (HGS), dual‐energy X‐ray absorptiometry‐measured appendicular lean mass index (ALM/kg) and body fat percentage (BF%) were included. SOP i was calculated as a sex‐specific equation integrating z‐scores (Z) of (BF%)—(HGS)—(ALM/kg). Cox regression and multivariable linear regression models were fitted to evaluate mortality risk and associated factors with SOP i , respectively. Subgroup analysis of SOP i changes was performed by linear mixed‐effects models. Results: In the total population ( n = 5888, age 69.5 ± 9.1 years, BMI 27.5 ± 4.3 kg/m 2 , 56.8% females) and over the 9.9‐year median follow‐up period, 1538 (26.1%) participants died. Each standard deviation (SD) increase in sex‐specific SOP i was associated with a 10% higher risk of premature death (HR = 1.10 [95%CI: 1.07; 1.13]). Thirteen factors were associated with high SOP i , such as reduced physical activity, higher triglyceride‐glucose index, HOMA‐IR, systemic inflammation, osteopenia, hypertension, liver steatosis, asthma, coronary heart disease, oral corticosteroid use, lower protein intake, lower quality of life and lower educational status. In participants with obesity, lower physical activity and/or insulin resistance ( n = 1682), a significantly higher and faster increase in SOP i was observed compared to participants without these factors (males: β = 2.63 [95%CI: 2.22; 3.03]; females: β = 2.90 [95%CI: 2.58; 3.23]). Conclusion: SOP i is a significant predictor of premature death and can identify associated factors, particularly useful among persons at risk of SO. SOP i is higher and increases faster in individuals with specific phenotypes. SOP i integrates prognosis information, which could be used as a risk indicator and for prevention of SO.
- 15 October 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (5) , e70099
Open AccessSarcopenic Obesity Phenotype Index (SOP i ): A Population‐Based Study
Background: Sarcopenic obesity (SO) is a clinical condition defined by the coexistence of high body fat mass and low muscle function and mass, which increases the risk of adverse health outcomes, including disability and mortality. Early detection and frequent monitoring of SO are essential for preventive interventions and management strategies. The current binary approach for SO diagnosis is limited in capturing the spectrum of SO or its progression over time. The main objective of this study was to develop a continuous SOP i that integrates diagnostic criteria such as muscle function and body composition. We aimed to evaluate the association between SOP i and all‐cause mortality, to identify baseline‐related factors with SOP i and to assess changes in the SOP i over time. Methods: Participants from the Rotterdam Study with baseline and follow‐up measures of handgrip strength (HGS), dual‐energy X‐ray absorptiometry‐measured appendicular lean mass index (ALM/kg) and body fat percentage (BF%) were included. SOP i was calculated as a sex‐specific equation integrating z‐scores (Z) of (BF%)—(HGS)—(ALM/kg). Cox regression and multivariable linear regression models were fitted to evaluate mortality risk and associated factors with SOP i , respectively. Subgroup analysis of SOP i changes was performed by linear mixed‐effects models. Results: In the total population ( n = 5888, age 69.5 ± 9.1 years, BMI 27.5 ± 4.3 kg/m 2 , 56.8% females) and over the 9.9‐year median follow‐up period, 1538 (26.1%) participants died. Each standard deviation (SD) increase in sex‐specific SOP i was associated with a 10% higher risk of premature death (HR = 1.10 [95%CI: 1.07; 1.13]). Thirteen factors were associated with high SOP i , such as reduced physical activity, higher triglyceride‐glucose index, HOMA‐IR, systemic inflammation, osteopenia, hypertension, liver steatosis, asthma, coronary heart disease, oral corticosteroid use, lower protein intake, lower quality of life and lower educational status. In participants with obesity, lower physical activity and/or insulin resistance ( n = 1682), a significantly higher and faster increase in SOP i was observed compared to participants without these factors (males: β = 2.63 [95%CI: 2.22; 3.03]; females: β = 2.90 [95%CI: 2.58; 3.23]). Conclusion: SOP i is a significant predictor of premature death and can identify associated factors, particularly useful among persons at risk of SO. SOP i is higher and increases faster in individuals with specific phenotypes. SOP i integrates prognosis information, which could be used as a risk indicator and for prevention of SO.
- Open Access
- 27 July 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (5)
Oral corticosteroid use and sarcopenia-related traits in older people with chronic airway disease: a population-based study
Background: Sarcopenia is characterised by two major phenotypic components: low handgrip strength (HGS) and appendicular skeletal muscle index (ASMI). Oral corticosteroid (OCS) use is an important medication for acute respiratory exacerbations in patients with COPD and asthma. However, the association of OCS and sarcopenia components in older people is largely unexplored. The aim of this study was to examine the association between OCS use and HGS or ASMI in the general population and explore interactions with chronic airway diseases. Methods: From the population-based Rotterdam Study, 5054 participants (age 69.0±8.8 years; 56% females) were included in the cross-sectional analysis and 1324 in the longitudinal analysis. Associations between OCS and muscle strength and mass were analysed using linear regression models adjusted for age, sex, fat %, height, kidney function, smoking and comorbidities. Results: At baseline, ever-OCS users had lower handgrip strength (β= −0.48, 95% CI −0.84– −0.12) than never-OCS users, with cumulative frequency (≥10 OCS prescriptions)-dependent effects (β= −1.25, 95% CI −2.16– −0.33). COPD ever-OCS users, but not asthma, had lower handgrip strength (β= −0.98, 95% CI −1.91– −0.06) and lower lean mass (β= −0.14, 95% CI −0.27– −0.01) than never-OCS users. After 5.6 years of follow-up in those free of sarcopenia traits at baseline, COPD ever-OCS users developed lower handgrip strength (β= −1.64, 95% CI −2.87– −0.40) with frequency (β= −3.64, 95% CI −6.57– −0.72) and duration (β= −1.51, 95% CI −2.87– −0.15) association compared to never-OCS users. Conclusions: OCS use is associated with a decline in handgrip strength in people with COPD in a cumulative frequency and duration-dependent manner. Routine muscle examination may be necessary for patients with COPD.
- 27 July 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (5)
Open AccessOral corticosteroid use and sarcopenia-related traits in older people with chronic airway disease: a population-based study
Background: Sarcopenia is characterised by two major phenotypic components: low handgrip strength (HGS) and appendicular skeletal muscle index (ASMI). Oral corticosteroid (OCS) use is an important medication for acute respiratory exacerbations in patients with COPD and asthma. However, the association of OCS and sarcopenia components in older people is largely unexplored. The aim of this study was to examine the association between OCS use and HGS or ASMI in the general population and explore interactions with chronic airway diseases. Methods: From the population-based Rotterdam Study, 5054 participants (age 69.0±8.8 years; 56% females) were included in the cross-sectional analysis and 1324 in the longitudinal analysis. Associations between OCS and muscle strength and mass were analysed using linear regression models adjusted for age, sex, fat %, height, kidney function, smoking and comorbidities. Results: At baseline, ever-OCS users had lower handgrip strength (β= −0.48, 95% CI −0.84– −0.12) than never-OCS users, with cumulative frequency (≥10 OCS prescriptions)-dependent effects (β= −1.25, 95% CI −2.16– −0.33). COPD ever-OCS users, but not asthma, had lower handgrip strength (β= −0.98, 95% CI −1.91– −0.06) and lower lean mass (β= −0.14, 95% CI −0.27– −0.01) than never-OCS users. After 5.6 years of follow-up in those free of sarcopenia traits at baseline, COPD ever-OCS users developed lower handgrip strength (β= −1.64, 95% CI −2.87– −0.40) with frequency (β= −3.64, 95% CI −6.57– −0.72) and duration (β= −1.51, 95% CI −2.87– −0.15) association compared to never-OCS users. Conclusions: OCS use is associated with a decline in handgrip strength in people with COPD in a cumulative frequency and duration-dependent manner. Routine muscle examination may be necessary for patients with COPD.
- Open Access
- 15 June 2022
- Published by Elsevier in Bone Reports
- Vol. 16, 101203
Assessing inflammatory-circulating proteomics as potential biomarkers for sarcopenia-traits in middle-aged and older people: a population-based study
- 15 June 2022
- Published by Elsevier in Bone Reports
- Vol. 16, 101203
Open AccessAssessing inflammatory-circulating proteomics as potential biomarkers for sarcopenia-traits in middle-aged and older people: a population-based study
- Open Access
- 23 December 2021
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 8 (1)
Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study
Background: Increasing evidence suggests that sarcopenia and a higher systemic immune-inflammation index (SII) are linked with morbidity in patients with COPD. However, whether these two conditions contribute to all-cause mortality in middle-aged and older patients with COPD or asthma is unclear. Therefore, we investigated the association between sarcopenia, SII, COPD or asthma and all-cause mortality in a large-scale population-based setting.Methods: Between 2009 and 2014, 4482 participants (aged >55 years; 57.3% female) from the population-based Rotterdam Study were included. COPD and asthma patients were diagnosed clinically and based on spirometry. Six study groups were defined according to the presence or absence of COPD or asthma and sarcopenia. Cox regression models were used to assess all-cause mortality in the study groups, adjusted for sex, age, body mass index, SII, smoking, oral corticosteroid use and comorbidities. In addition, all participants were categorised into sex-specific quartiles of SII, and mortality in these groups was compared.Results: Over a median follow-up of 6.1 years (interquartile range 5.0–7.2 years), 466 (10.4%) persons died. Independent of the presence of sarcopenia, participants with COPD had a higher risk of all-cause mortality (hazard ratio (HR) 2.13, 95% CI 1.46–3.12 and HR 1.70, 95% CI 1.32–2.18 for those with and without sarcopenia, respectively). Compared to lower SII levels, higher SII levels increased mortality risk even in people without sarcopenia, COPD or asthma.Conclusion: Middle-aged and older people with COPD, higher SII levels or sarcopenia had an independently increased mortality risk. Our study suggests prognostic usefulness of routinely evaluating sarcopenia and SII in older people with COPD or asthma.
- 23 December 2021
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 8 (1)
Open AccessSarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study
Background: Increasing evidence suggests that sarcopenia and a higher systemic immune-inflammation index (SII) are linked with morbidity in patients with COPD. However, whether these two conditions contribute to all-cause mortality in middle-aged and older patients with COPD or asthma is unclear. Therefore, we investigated the association between sarcopenia, SII, COPD or asthma and all-cause mortality in a large-scale population-based setting.Methods: Between 2009 and 2014, 4482 participants (aged >55 years; 57.3% female) from the population-based Rotterdam Study were included. COPD and asthma patients were diagnosed clinically and based on spirometry. Six study groups were defined according to the presence or absence of COPD or asthma and sarcopenia. Cox regression models were used to assess all-cause mortality in the study groups, adjusted for sex, age, body mass index, SII, smoking, oral corticosteroid use and comorbidities. In addition, all participants were categorised into sex-specific quartiles of SII, and mortality in these groups was compared.Results: Over a median follow-up of 6.1 years (interquartile range 5.0–7.2 years), 466 (10.4%) persons died. Independent of the presence of sarcopenia, participants with COPD had a higher risk of all-cause mortality (hazard ratio (HR) 2.13, 95% CI 1.46–3.12 and HR 1.70, 95% CI 1.32–2.18 for those with and without sarcopenia, respectively). Compared to lower SII levels, higher SII levels increased mortality risk even in people without sarcopenia, COPD or asthma.Conclusion: Middle-aged and older people with COPD, higher SII levels or sarcopenia had an independently increased mortality risk. Our study suggests prognostic usefulness of routinely evaluating sarcopenia and SII in older people with COPD or asthma.